Wall Street Zen Upgrades AbbVie (NYSE:ABBV) to “Strong-Buy”

AbbVie (NYSE:ABBV) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

A number of other analysts have also recently commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $258.00 price target on shares of AbbVie in a research report on Thursday, January 15th. Royal Bank Of Canada assumed coverage on AbbVie in a research report on Tuesday. They issued an “outperform” rating and a $260.00 target price on the stock. Evercore cut their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. Finally, UBS Group cut their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $231.69 on Friday. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market cap of $409.66 billion, a PE ratio of 98.17, a P/E/G ratio of 0.78 and a beta of 0.35. The business has a 50-day simple moving average of $224.34 and a two-hundred day simple moving average of $222.94.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie will post 12.31 earnings per share for the current fiscal year.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter. State Street Corp grew its holdings in shares of AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after buying an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC raised its position in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after buying an additional 4,190,487 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after buying an additional 1,517,222 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after buying an additional 356,394 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital Markets initiated coverage with an Outperform rating and a $260 price target, arguing AbbVie’s growth is durable and the shares have been punished by short‑term competitive concerns — a bullish analyst catalyst that likely supported buying interest. RBC Launches AbbVie Coverage
• Positive Sentiment: The U.S. Justice Department publicly backed AbbVie’s challenge to Colorado’s 340B guidance, giving the company federal support in a case that could affect how discounts are applied and future margin outcomes in that program. DOJ backs AbbVie in 340B fight
• Positive Sentiment: Federal agencies also supported AbbVie’s position in Colorado in separate coverage, reinforcing regulatory/legal momentum in the company’s favor that could protect 340B economics if courts rule similarly. Feds back AbbVie in Colorado 340B fight
• Positive Sentiment: AbbVie received FDA approval for a first‑in‑class, all‑oral fixed‑duration regimen for untreated CLL and announced a $380M U.S. manufacturing buildout to support neuroscience and obesity programs — both add to medium‑term revenue and capacity upside. AbbVie’s CLL Breakthrough And US$380m Build Out
• Positive Sentiment: AbbVie reported fresh real‑world/post‑marketing data updates for upadacitinib (Rinvoq) in teens with eczema — data investors should watch for uptake and label/market expansion implications for a key growth franchise. Upadacitinib Study in Teens
• Neutral Sentiment: Zacks highlights AbbVie as a top long‑term value stock based on style scores — a framing piece that supports a buy thesis but doesn’t present new company‑specific catalysts. Why AbbVie is a Top Value Stock
• Neutral Sentiment: Dividend and longer‑term outlook pieces (Seeking Alpha / Motley Fool) reiterate AbbVie’s income profile and buy‑and‑hold case, helpful context for income investors but unlikely to trigger near‑term moves alone. Health Care Q4 Dividend Roundup
• Negative Sentiment: A Tennessee court rejected AbbVie’s challenge to that state’s contract‑pharmacy law, a loss that keeps legal/regulatory uncertainty around 340B implementation and potential margin headwinds in some states. AbbVie Loses Challenge in Tennessee

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.